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ABSTRACT
Background UK estimates of age related macular
degeneration (AMD) occurrence vary.
Aims To estimate prevalence, number and incidence of
AMD by type in the UK population aged $50 years.
Methods Age-speciﬁc prevalence rates of AMD
obtained from a Bayesian meta-analysis of AMD
prevalence were applied to UK 2007e2009 population
data. Incidence was estimated from modelled
age-speciﬁc prevalence.
Results Overall prevalence of late AMD was 2.4% (95%
credible interval (CrI) 1.7% to 3.3%), equivalent to
513000 cases (95% CrI 363000 to 699000); estimated
to increase to 679000 cases by 2020. Prevalences were
4.8% aged $65 years, 12.2% aged $80 years.
Geographical atrophy (GA) prevalence rates were 1.3%
(95% CrI 0.9% to 1.9%), 2.6% (95% CrI 1.8% to 3.7%)
and 6.7% (95% CrI 4.6% to 9.6%); neovascular AMD
(NVAMD) 1.2% (95% CrI 0.9% to 1.7%), 2.5% (95% CrI
1.8% to 3.4%) and 6.3% (95% CrI 4.5% to 8.6%),
respectively. The estimated number of prevalent cases of
late AMD were 60% higher in women versus men
(314000 cases in women, 192000 men). Annual
incidence of late AMD, GA and NVAMD per 1000
women was 4.1 (95% CrI 2.4% to 6.8%), 2.4 (95% CrI
1.5% to 3.9%) and 2.3 (95% CrI 1.4% to 4.0%); in men
2.6 (95% CrI 1.5% to 4.4%), 1.7 (95% CrI 1.0% to 2.8%)
and 1.4 (95% CrI 0.8% to 2.4%), respectively. 71000
new cases of late AMD were estimated per year.
Conclusions These estimates will guide health and
social service provision for those with late AMD and
enable estimation of the cost of introducing new
treatments.
INTRODUCTION
Age related macular degeneration (AMD) is a major
cause of ocular morbidity in high income countries,
accounting for over half of blind and partial sight
certiﬁcations in the UK.
1 However, the number
registered underestimates the number with visual
loss caused by the condition, as it excludes those
who choose not to be registered. Moreover, this
ﬁgure does not include the appreciable number of
those with the condition who do not qualify for
registration. There have been a number of attempts
to quantify the number with AMD in the UK,
23
but these estimates differ, and are heavily dependent
on the characteristics of studies used to generate the
ﬁgures; in particular, age of the study sample, case
deﬁnition of AMD, and whether fundus imaging
and independent grading have been used. We have
previously quantiﬁed the magnitude of effect these
characteristics have on the prevalence of AMD.
4
While a treatment for geographical atrophy
(GA) remains to be established, treatments for
neovascular AMD (NVAMD) using photodynamic
therapy and antivascular endothelial growth
factors exist; the latter is being increasingly used to
limit progression of the condition.
5 In order to
plan adequate healthcare provision, estimates of
incidence are required, but these differ between
studies.
6e9 Estimates suggest that the number
eligible for treatment has increased ﬁvefold over
a relatively short period.
10e12 These estimates are
based on certiﬁcation data
10 or from a small
number of population cohorts, which have
followed up individuals from 5 to 15 years.
81 31 4
Extrapolating from these studies to the population
at large is highly sensitive to the age distribution of
the study population and duration of follow-up. A
more robust approach is to use age-speciﬁc preva-
lence rates of late AMD. Data modelled from many
studies allow a wider range of ages to be repre-
sented compared with the limits of a single inci-
dence study. Robust estimates of prevalence at
older ages are of particular importance as this is
where late AMD is most prevalent. We have
therefore applied age-speciﬁc prevalence rates from
our recent review (modelled using Bayesian meta-
analysis over a wide range of ages)
4 to UK popu-
lation data to provide estimates of the number of
prevalent cases and incidence of late AMD, GA and
NVAMD.
MATERIALS AND METHODS
Age-speciﬁc prevalence data
We estimated the age-speciﬁc prevalence of late
AMD, GA and NVAMD (for men, women and
genders combined) using a Bayesian meta-analysis
of 31 populations studies with a combined popu-
lation of 57173 (with 1571, 455 and 464 cases of
late AMD, GA and NVAMD cases, respectively).
4
These prevalence estimates represent the most
complete meta-analysis of AMD prevalence in
white populations (from Europe, North America
and Australia) largely similar to the middle-aged and
older population of the UK. Prevalence estimates
allowed for study characteristics, such as age of the
sample, examination methods and deﬁnitions of
disease (internationally recognised deﬁnitions being
preferred).
15 16 Prevalence estimates from the
Bayesian model were produced by year from 50 to
97 years of age (the oldest reported age in the
studies included in the meta-analysis) for men,
women and genders combined (Web table 1) based
on‘either eye’ case deﬁnitions (including at least one
eye, worst eye, one or both eyes) using the Inter-
national Classiﬁcation System or Wisconsin Age-
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Laboratory scienceRelated Maculopathy Grading System and fundus photog-
raphy.
15 16 A 95% credible interval (CrI) of prevalence by year
was also obtained from the Bayesian model: a 95% CrI represents
the range of values within which the true prevalence is expected
to lie with 95% probability.
UK population characteristics
Demographic characteristics for the population of the UK were
obtained from the Ofﬁce of National Statistics. The mean yearly
population from 50 to 97 years of age was obtained from esti-
mates for the years 2007e2009.
17e19 Prevalence estimates for
each year of age from the Bayesian model were applied to these
population ﬁgures. The Ofﬁce of National Statistics also
provides estimates of the probability of dying at each year of
age,
20 as well as projections of UK population numbers over
time.
21 Population projections up to 2020 were used as data
beyond this may be less reliable.
Estimating incidence from prevalence
Estimating incidence from age-speciﬁc prevalence data has been
carried out previously for open angle glaucoma.
22 We used this
method to estimate the annual incidence by age of late AMD,
GA and NVAMD in men and women between the ages of 50 and
97 years. Prevalence estimates for each year of age were used to
determine the probability of AMD per year of age. The proba-
bility is then converted into an incidence assuming that: (i) the
outcome of interest is life-long after diagnosis; (ii) mortality risk
is the same in those with and without the disease; and (iii) the
disease is stable in the population (with risk factors for the
condition remaining constant).
RESULTS
The prevalence of late AMD standardised to the UK population
aged 50 years or more was 2.4% (95% CrI 1.7% to 3.3%),
increasing to 4.8% (95% CrI 3.4% to 6.6%) in those aged 65 years
or more and 12.2% (95% CrI 8.8% to 16.3%) in those aged
80 years or more. Prevalences for GA were 1.3% (95% CrI 0.9%
to 1.9%), 2.6% (95% CrI 1.8% to 3.7%) and 6.7% (95% CrI
4.6% to 9.6%) and for NVAMD 1.2% (95% CrI 0.9% to 1.7%),
2.5% (95% CrI 1.8% to 3.4%) and 6.3% (95% CrI 4.5% to 8.6%),
respectively. These estimates applied to the UK population
result in approximately 513000 prevalent cases of late AMD
(95% Cr I 363000 to 699000), 276000 cases of GA (95% CrI
188000 to 396000) and 263000 cases of NVAMD (95% CrI
185000 to 361000). UK age-speciﬁc prevalence rates of late
AMD, GA and NVAMD are shown for different age groups in
Web table 1 for men and women separately; the number of cases
is shown graphically in ﬁgure 1. The Bayesian model showed
little gender difference in GA prevalence, but slightly higher
prevalence in women for late AMD, which was explained by the
higher prevalence of NVAMD in women.
4 Application of these
prevalence rates to the UK population, in combination with
larger numbers of older women at older ages, results in marked
gender differences in the number of prevalent cases, especially
between 80 and 90 years of age (ﬁgure 1). Overall, the estimated
number of prevalent cases of late AMD was 60% higher in
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Figure 1 Number of prevalent cases (in thousands) of late age related macular degeneration (AMD), geographical atrophy (GA) and neovascular
AMD (NVAMD) in men (open blue squares) and women (open red) by 1-year age groups. The dashed blue and red lines are the 95% credible intervals
for men and women, respectively.
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Laboratory sciencewomen compared with men, with 314000 cases in women and
192000 in men. Beyond 90 years of age, there is a sharp decline
in the number of AMD cases in both genders (ﬁgure 1). Appli-
cation of these prevalence rates to population projections
suggests a linear increase in the number of AMD cases by 2020.
There are estimated to be 394000 women and 285000 men
(679000 in all) with late AMD by 2020 (ﬁgure 2), which is an
increase of a third. Data for GA and NVAMD show similar
increases (data available from the authors).
The overall number of incident cases in those aged over 50
years for late AMD, GA and NVAMD in women was 4.1 (95%
CrI 2.4 to 6.8), 2.4 (95% CrI 1.5 to 3.9) and 2.3 (95% CrI 1.4 to
4.0) in the UK per 1000 per year; in men it is 2.6 (95% CrI 1.5 to
4.4), 1.7 (95% CrI 1.0 to 2.8) and 1.4 (95% CrI 0.8 to 2.4),
respectively. Incidence by age (ﬁgure 3, Web table 2) shows
higher rates of NVAMD in women, and slightly higher rates in
women for late AMD. Application of these incidence rates to the
UK population results in higher numbers of new late AMD, GA
and NVAMD cases per year in women compared with men,
being most marked between 80 and 90 years of age, with a sharp
decline thereafter. The total number of new cases of late AMD,
GA and NVAMD per year in men and women was 25344 (95%
CrI 14500 to 43900), 16700 (95% CrI 10200 to 27200) and
13400 (95% CrI 7900 to 23200) and 45900 (95% CrI 26600 to
77000), 27000 (95% CrI 16800 to 44000) and 26400 (95% CrI
15800 to 45100), respectively.
DISCUSSION
We have applied ﬁndings from a recent systematic review
4 based
on 31 populations of European ancestry with a wide age range
(50e97 years) (including 18 populations from Western Europe
with four from the UK
23e26) to the population of the UK to
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Figure 2 Projected number of prevalent cases (in thousands) of late
age related macular degeneration (AMD) in men (blue line) and women
(red line) and combined (black line) from 2010 to 2020.
Figure 3 Graphs on the left had side
represent the annual incidence (number
per 1000) of late age related macular
degeneration (AMD), geographical
atrophy (GA) and neovascular AMD
(NVAMD) in men (open blue squares)
and women (open red circles). The
dashed blue and red lines are the 95%
credible intervals for men and women,
respectively. Graphs on the right hand
side represent number of new cases
per year in men (blue line) and women
(red line) as applied to the UK
population.
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Laboratory sciencemodel the number of prevalent cases of late AMD, GA and
NVAMD. We estimate that there are currently 513000 (95% Cr I
363000 to 699000) prevalent cases of late AMD, 276000 cases of
GA (95% CrI 188000 to 396000) and 263000 cases of NVAMD
(95% CrI 185000 to 361000). With knowledge of the probability
of death by age, and assuming similar mortality in those with
and without AMD, the annual number of incident cases is
71200 (95% CrI 41100 to 120900), 43700 (95% CrI 27000 to
71200) and 39700 (95% CrI 23700 to 68300), respectively.
While women have slightly higher age-speciﬁc prevalence rates
of late and NVAMD, it is the much greater number of older
women in the UK that results in the gender difference in the
number of prevalent and incident cases (ﬁgures 1 and 3). This
explains the perceived view of an abundance of older women
presenting to medical retina clinics with AMD.
How do these numbers compare with previous estimates?
Numbers from this study are similar to, but more precise than,
our earlier estimates of prevalent cases of 191000 (95% CI
171000 to 310000) with GA and 271000 (95% CI 179000 to
405000) with NVAMD, which combine to give 462000 with
late AMD within the present study’s CrIs. Our CrIs also include
recent point estimates
3 derived by applying ﬁndings from
another review
27 to the UK population (although our NVAMD
estimates are lower). There have also been a number of attempts
to estimate incidence of NVAMD in the UK in order to plan
treatment demand and costs.
28 We are not aware of any UK
estimates for GA incidence, probably because this is less of
a priority given lack of effective treatment (although the need
for low vision services remains). Initial estimates of NVAMD
requiring photodynamic therapy in England and Wales suggested
5000 patients per year, estimated from either blind and partial
sight registrations
10 or from two non-UK prospective cohort
studies.
11 29 30 With the introduction of newer therapies for
NVAMD,
5 potentially suitable for classic and occult types of
choroidal neovascularisation, estimates of the number eligible
for treatment have increased from 7000 to 26000 patients per
year.
28 The source of these estimates is unclear,
28 but Novartis
Pharmaceuticals UK also suggested 26000 new cases of wet
AMD in the UK per year, reported as being calculated from our
earlier review of prevalence.
23 1This ﬁgure is commensurate
with estimates that there are 13000 to 37000 incident cases of
NVAMD in England and Wales per year,
28 based on two
prospective cohort studies in the Netherlands
32 and Australia.
8
Our prediction of incidence is higher, but our CrIs are wide and
include many of the previously reported estimates (including the
popular ﬁgure of 26000 annual cases of NVAMD). Our overall
and age-speciﬁc annual incidence rates (Web table 2) also appear
to be higher than those calculated
33 from ‘ﬁrst eye’ cumulative
AMD incidence in other studies.
6e9 The exponential rise in
prevalence and incidence rates with age (with prevalence rates of
late AMD quadrupling per decade)
4 makes direct comparisons
with estimates from individual studies difﬁcult because they are
heavily dependent on the age distribution of the sample at
baseline and period of follow-up. Representation of data from
older people (especially those aged 80 years or more) is needed to
avoid underestimation of population numbers with late stage
AMD (while recognising that the number with or developing
AMD in a population will ultimately fall with age due to
increased mortality). Unfortunately, any single prospective
study has limited information on incidence at older ages when
AMD is particularly prevalent. Although there are some studies
with long durations of follow-up (up to 15 years),
81 31 4results
are generally reported as 5- or 10-year incidence rates making it
difﬁcult to determine the annual incidence without knowledge
of the change in pattern of incidence with time/age. Therefore,
estimating incidence from prevalence, particularly at older ages,
is an efﬁcient approach and likely to be more accurate in the
absence of large studies with follow-up at all ages (particularly
at older ages where follow-up is more problematic).
Our numbers are calculated from either eye prevalence rates.
4
While this might overestimate any potential visual loss associ-
ated with the condition (especially when both eyes are used),
this is appropriate when estimating potential therapeutic costs
as bilateral disease is less common, and presence of any disease
may warrant treatment. Using ‘either eye’ case deﬁnitions will
result in some individuals being counted in GA and NVAMD
groups, but this number is likely to be small. While this may
partly explain why the estimated number with GA and
NVAMD combined is higher than those estimated with late
AMD, a more plausible explanation is that the estimates of
prevalence of late AMD are more precise as they are estimated
from a meta-analysis of a larger number of studies (31 studies)
compared with those for GA and NVAMD (23 studies). Similar
to earlier work estimating incidence of glaucoma from age-
speciﬁc prevalence,
22 our calculations assume that: (i) AMD is
life-long after diagnosis, (ii) overall mortality risks are the same
in those with and without AMD and (iii) AMD is stable in the
population (with risk factors for the condition remaining the
same). The ﬁrst assumption is correct, there is no consistent
evidence to argue against the second
34e36 and we have found no
strong evidence in our meta-analysis that late AMD prevalence
has changed over time,
4 although a recent study suggested that
the prevalence of AMD (including early and late forms) may
have fallen,
37 attributed to improved diets and reductions in
smoking prevalence.
38 The estimation of incidence for older age
groups is the most plausible explanation for our higher numbers,
with the peak in number of prevalent and incident cases being
just below 90 years of age. The noticeable kink in the decline
beyond 90 years of age reﬂects the sharp decline in births during
World War I (1914e1918), followed by the rapid postwar baby
boom (approximately 1920).
39 While our estimates of NVAMD
incidence are high, this may not reﬂect the number in need of
treatment. The type of NVAMD on presentation cannot be
estimated from these data, that is, classic or occult, although
limited evidence from other sources suggests a ratio of 2:1.
11
Moreover, older patients may be too frail to beneﬁt/undergo
treatment.
In the absence of any large, geographically representative
population study of AMD in the UK, this review provides the
best estimates of the number of prevalent and incident cases of
late AMD, GA and NVAMD in the largely white older popula-
tion of the UK. While most of the current older UK population
are white (96% white population in England and Wales aged
$65 years),
40 this is likely to diminish in the future. However,
evidence suggests similar or lower rates of AMD in populations
of non-European ancestry.
27 41 Our estimates are based on
pooled ﬁndings from studies carried out in white populations
from North America, Australia and Europe with shared ancestry
(including recent
23 and historical studies in the UK
24e26). All
studies contributed to the prevalence estimates used to calculate
incidence. We adjusted for differences between studies in
methodology which may have biased rate estimates
24e26 (such
as no fundus imaging and study-speciﬁc as opposed to interna-
tionally recognised disease deﬁnitions).
15 16 Projections over the
next decade suggest that the number of prevalent cases of late
AMD will increase steadily by a third by 2020 due to population
ageing. These evidence based estimates can be used to help plan
social and healthcare provision for the present and the future.
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